SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
IVERIC bio, Inc. (ISEE) .
Criteria proven by this page:
- VALUE (20/100, Fail) — analyst consensus target implies downside from the current price ($32.75, 18%).
- Analyst consensus target $32.75 (-18% downside) — analysts see meaningful downside risk at the current price level.
Overall SharesGrow Score: 26/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
20/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
67/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ISEE
Valuation Multiples
P/E (TTM)0.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio0.00
EV/EBITDA0.0
Per Share Data
EPS (TTM)$-1.45
Book Value / Share$0.00
Revenue / Share$0.00
FCF / Share$0.00
Yields & Fair Value
Earnings YieldN/A
Dividend Yield0.00%
Analyst Target$32.75 (-18%)
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2013 |
$-5.68 |
$0.00 |
$-51.15M |
- |
| 2014 |
$-2.95 |
$41.26M |
$-98.19M |
-238% |
| 2015 |
$-3.06 |
$51.51M |
$-105.72M |
-205.3% |
| 2016 |
$-5.45 |
$50.91M |
$-193.42M |
-379.9% |
| 2017 |
$3.17 |
$209.98M |
$114.21M |
54.4% |
| 2018 |
$1.70 |
$0.00 |
$63.09M |
- |
| 2019 |
$-1.39 |
$0.00 |
$-58.86M |
- |
| 2020 |
$-1.14 |
$0.00 |
$-84.55M |
- |
| 2021 |
$-1.12 |
$0.00 |
$-114.24M |
- |
| 2022 |
$-1.45 |
$0.00 |
$-175.75M |
- |
